[Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].

@article{Elikowski2015HemoptysisDC,
  title={[Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].},
  author={Waldemar Elikowski and Małgorzata Małek and Marcin Skowroński and Dariusz Wr{\'o}blewski and Paweł Skrzywanek and Krystyna Zawilska},
  journal={Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego},
  year={2015},
  volume={39 232},
  pages={227-30}
}
UNLABELLED Rivaroxaban, a selective inhibitor of active factor X, is metabolized by cytochrom P450 3A4 (CYP3A4) and is a substrate for transporter protein--P-glycoprotein (P-gp). Amiodarone, an antiarrhytmic agent, is classified as moderate CYP3A4 and P-gp inhibitor. A CASE REPORT A 75-year-old male, who underwent lobectomy for bronchiectasis many years… CONTINUE READING